Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature

European Respiratory Review

Volumn 21, Issue 126, 2012, Pages 355-361

  Nalysnyk, Luba ^a   Cid Ruzafa, Javier ^a   Rotella, Philip ^a   Esser, Dirk ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Boehringer Ingelheim GmbH   (United Kingdom)

Author keywords

Cryptogenic fibrosing alveolitis; Epidemiology; Interstitial lung disease; Usual interstitial pneumonia

Indexed keywords

AGE DISTRIBUTION; EUROPE; FIBROSING ALVEOLITIS; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; PREVALENCE; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREND STUDY; UNITED STATES;

AGE DISTRIBUTION; EUROPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; PREVALENCE; SEX DISTRIBUTION; UNITED STATES;

EID: 84870765540     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00002512     Document Type: Review

References (36)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
3. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3: 8.
4. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285-292.
5. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011; 184: 842-847.
6. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
7. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985.
8. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462-467.
9. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
10. Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol 2002; 34: 23-29.
11. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis a population-based study. Chest 2010; 137: 129-137.
12. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342.
13. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103: 1122-1129.
14. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia, in the period 1981-1990. Internista 1995; 3: 105-108.
15. Ohno S, Nakaya T, Bando M, et al. Idiopathic pulmonary fibrosis-results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008; 13: 926-928.
16. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-816.
17. Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001; 56: 163-172.
18. Thomeer MJ, Costabel U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J 2001; 18: Suppl. 32, 114s-118s.
19. Tinelli C, De Silvestri A, Richeldi L, et al. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: Suppl. 1, S4-S8.
20. von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003; 97: 428-435.
21. Xaubet A, Ancochea J, Morell F, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 64-70.
22. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
23. U.S. Food and Drug Administration. Definition of Disease Prevalence for Therapies Qualifying under the Orphan Drug Act. www.fda.gov/ForIndustry/DevelopingProductsforRareDiseases Conditions/HowtoapplyforOrphanProductDesignation/Definitionof DiseasePrevalence/ucm135130.htm Date last updated: July 9, 2010. Date last accessed: March 12, 2012.
24. European Medicines Agency. Orphan Designation. www.ema. europa.eu/ema/index.jsp?curl5pages/regulation/general/general_ content_000029.jsp&mid5WC0b01ac05800240ce Date last accessed: March 12, 2012.
25. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.
26. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-599.
27. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
28. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000; 152: 307-315.
29. Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 2005; 49: 259-265.
30. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146-1152.
31. Egan JJ, Stewart JP, Hasleton PS, et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995; 50: 1234-1239.
32. Lederer DJ, Arcasoy SM, Barr RG, et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: a UNOS/OPTN database analysis. Am J Transplant 2006; 6: 2436-2442.
33. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127: 2034-2041.
34. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698-705.
35. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
36. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.